Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome

Multiple Sclerosis Journal

Volumn 19, Issue 8, 2013, Pages 1074-1083

  Comi, Giancarlo ^a   Martinelli, Vittorio ^a   Rodegher, Mariaemma ^a   Moiola, Lucia ^a   Leocani, Letizia ^a   Bajenaru, Ovidiu ^b   Carra, Adriana ^c   Elovaara, Irina ^d   Fazekas, Franz ^e   Hartung, Hans Peter ^f   Hillert, Jan ^g   King, John ^h   Komoly, Samuel ⁱ   Lubetzki, Catherine ^j   Montalban, Xavier ^k   Myhr, Kjell Morten ^l   Preziosa, Paolo ^m   Ravnborg, Mads ⁿ   Rieckmann, Peter ^o   Rocca, Maria A ^m   Wynn, Daniel ^p   Young, Carolyn ^q   Filippi, Massimo ^m   more..

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^d UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^e MEDICAL UNIVERSITY OF GRAZ   (Austria)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h ROYAL MELBOURNE HOSPITAL   (Australia)

ⁱ UNIVERSITY OF PÉCS   (Hungary)

^j PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^k HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^l HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^m SAN RAFFAELE HOSPITAL   (Italy)

ⁿ ODENSE UNIVERSITY HOSPITAL   (Denmark)

^o UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^p Consultants in Neurology Multiple Sclerosis Centre Department of Clinical Research ^*  (United States)

^q WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

more..

Author keywords

brain atrophy; Clinically definite multiple sclerosis; clinically isolated syndrome (CIS); EDSS; glatiramer acetate; MRI; relapse

Indexed keywords

GLATIRAMER; PLACEBO;

ADULT; ARTICLE; BRAIN ATROPHY; COMPARATIVE STUDY; CONTROLLED STUDY; DEMYELINATING DISEASE; DIFFUSION WEIGHTED IMAGING; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THERAPY DELAY;

EID: 84879752237     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512469695     Document Type: Article

References (20)

1. DeStefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol. 2001 ; 58: 65-70 (Pubitemid 32053209)
2. Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part I: Natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol. 2005 ; 4: 281-288 (Pubitemid 40545039)
3. Thrower BW. Clinically isolated syndromes. Neurology. 2007 ; 68: S12 - S15
4. Trapp BDP, Peterson JB, Ransohoff RMM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998 ; 338: 278-285
5. Comi G. Early treatment. Neurol Sci. 2006 ; 27: S8 - S12
6. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): A randomised, double-blind, placebo-controlled trial. Lancet. 2009 ; 374: 1503-1511
7. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology. 1983 ; 33: 1444-1452 (Pubitemid 14237132)
8. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol. 1983 ; 13: 227-231 (Pubitemid 13158528)
9. Smith SM, De Stefano N, Jenkinson M, et al. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr. 2001 ; 25: 466-475 (Pubitemid 32440803)
10. Tortorella C, Codella M, Rocca MA, et al. Disease activity in multiple sclerosis studied by weekly triple-dose magnetic resonance imaging. J Neurol. 1999 ; 246: 689-692 (Pubitemid 29417851)
11. Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001 ; 49: 290-297 (Pubitemid 32202781)
12. Neurologic impairment 10 years after optic neuritis. Arch Neurol. 2004 ; 61: 1386-1389
13. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: A systematic review. Arch Neurol. 2006 ; 63: 1686-1691 (Pubitemid 44925075)
14. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain. 2003 ; 126: 770-782 (Pubitemid 36372978)
15. Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol. 2009 ; 8: 987-997
16. Pittock SJ. Uncertain BENEFIT of early interferon beta-1b treatment. Lancet Neurol. 2009 ; 8: 970-971
17. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006 ; 66: 678-684 (Pubitemid 43739821)
18. Rovaris M, Comi G, Rocca MA, et al. Long-term follow-up of patients treated with glatiramer acetate: A multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler. 2007 ; 13: 502-508 (Pubitemid 46796510)
19. Arnold DH, Narayanan S, Antel S. Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: Evidence from the PreCISe trial. Mult Scler. 2008 ; 14: S10
20. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: Results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler. 2010 ; 16: 342-350